Vlachojannis GJ, Wilschut JM, Vogel RF, et al. - In view of the recommendation of providing early treatment with a potent oral platelet P2Y12 inhibitor to patients presenting with ST-segment elevation myocardial infarction (STEMI) planned to undergo primary percutaneous coronary intervention (pPCI), researchers sought to determine the impact on coronary reperfusion of crushed P2Y12 inhibitor tablets, which result in more prompt and potent platelet inhibition via performing a randomized controlled, multicenter trial. In this trial, 727 STEMI patients who planned to undergo pPCI were enrolled and were assigned to receive in the ambulance, before transfer either crushed or integral tablets of prasugrel loading dose (LD). Findings indicated no correlation of prehospital administration of crushed prasugrel tablets with improved thrombolysis in myocardial infarction 3 flow in the infarct-related artery pre-pPCI or complete ST-segment resolution 1h post-pPCI in patients presenting with STEMI planned for pPCI.